Abstract: The present invention relates to a method and system for reducing water consumption in a membrane dealcoholization process. The system comprises a dealcoholization section and a polishing section, where the polishing section comprises one or more membrane polishing units with recirculation of streams.

Abstract: A microfluidic apparatus for culturing cells comprising: a microfluidic device (10) comprising: a collection reservoir (36) for collecting fluid, wherein the collection reservoir (36) is at least partially closed at a first end and comprises at least one outlet (38) at or adjacent to the at least partially closed first end; a fluid channel and an inlet coupling the fluid channel to the collection reservoir (36); wherein the apparatus further comprises: at least one separable material layer configured to be interfaced with the at least one outlet (38) wherein the at least one separable material layer comprises absorbent properties for controlling fluid flow from the at least one outlet (38).

Abstract: A docking device for receiving a portable device. The docking device includes a base including a substantially planar upper surface for supporting a portable device. The docking device includes an array of a plurality of engagement members. Each engagement member in the plurality of engagement members includes a fixed body protruding upwardly from the substantially planar upper surface of the base. Each engagement member includes a spring including a fixed end portion and a free end portion for engagement with the portable device. The fixed end portion interfaces with the fixed body. The free end portion protrudes from the fixed end portion obliquely towards the substantially planar upper surface of the base. The free end being movable along a deformable gap between a first surface of the fixed body and a second surface of the spring.

Abstract: To perform subculture at an appropriate timing according to the actual state of cells, the subculture timing determination method includes an image-capturing step of photographing cells at a plurality of predetermined points of a culture vessel at a first photographing time point to obtain the cells as a cell image of each point of the plurality of predetermined points at the first photographing time point, a primary information obtaining step of obtaining primary information of the cells photographed in the cell image of each point at the first photographing time point, a statistical index value obtaining step of calculating a statistical index value of the primary information of the cells, and a determination step of performing determination that a photographing time point corresponding to a time point at which the statistical index value reaches a predetermined threshold value is a time point at which a subculture timing is reached.

Abstract: Process for the preparation of vorasidenib using N,N?-bis[(2R)-1,1,1-trifluoropropan-2-yl]triimidodicarbonic diamide hydrochloride

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Abstract: Disclosed are an oxadiazole compound having a structure of formula (I), a pharmaceutical composition comprising same, and the use thereof as an HDAC6 inhibitor.

Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Abstract: Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefore, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Abstract: The present invention belongs to the field of pharmaceuticals, and particularly relates to a tricyclic compound, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, a method for preparing same, a pharmaceutical composition comprising same, and uses thereof.

Abstract: Disclosed is a novel meta-polyhedral oligomeric silsesquioxane (meta-POSS) compound as a modified polyhedral oligomeric silsesquioxane, which is a polysiloxane-based compound, a preparation method thereof, and a composition containing the meta-POSS compound prepared by the preparation method. The novel meta-POSS compound is characterized by including a structural unit of —Si—O—R2-O—Si—. R2 is —(CH2)2—, —(CH2)3—, —(CH2)4—, —(CH2)3—, —(CH2)6—, —(CH2)8—, —(CH2)10—, or —(CH2)12—.

Abstract: Monoorgano tin trialkoxide compounds having chemical formula R?SnX3 and containing less than about 5 mol % R?2SnX2 are described. R? is an optionally substituted organic substituent having about 1 to about 20 carbon atoms and each X is independently ORf, wherein Rf is a fluorinated organic substituent having about 1 to about 20 carbon atoms. Methods for synthesizing and purifying these compounds are also provided. The monoorgano tin compounds may be used for the formation of high-resolution EUV lithography patterning precursors and are attractive due to their high purity and minimal concentration of diorgano tin impurities.

Abstract: Organometallic complexes are described which are useful as pre-polymerization catalysts which may form part of olefin polymerization catalyst systems. The catalyst systems find use in the polymerization of ethylene, optionally with one or more C3-12 alpha-olefin comonomers. The organometallic complexes are broadly represented by formula I: wherein L is a bridging group containing a contiguous chain of atoms connecting P with Cy, wherein the contiguous chain contains 2 or 3 atoms and wherein Cy is a cyclopentadienyl-type ligand. The olefin polymerization catalyst system is effective at polymerizing ethylene with alpha-olefins in a solution phase polymerization process at high temperatures and produces ethylene copolymers with high molecular weight and high degrees of alpha-olefin incorporation. Pre-metallation compounds, metallation processes and synthetic methods to make the organometallic complexes as well as polymerization processes are also described.

Abstract: A composite material for an organic solar cell including a polyoxometalate (POM) cluster and a self-assembled monolayer (SAM) of a carbazole-based compound. The method for preparing the composite material and the use of such a composite material are also addressed.

Abstract: Disclosed are messenger RNA molecules and related compositions incorporating a 4?-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4?-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.

Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

Abstract: The present invention relates to a method for reducing lipopolysaccharides activity and/or lipopolysaccharides in a collagen-containing and/or collagen-derived product and products obtained by the method. The method comprises the steps of providing a collagen-containing and/or collagen-derived product comprising lipopolysaccharides, contacting the collagen-containing and/or collagen-derived product comprising lipopolysaccharides with a polyglycol ether of a fatty alcohol to provide a mixture and recovering a collagen-containing and/or collagen-derived product.

Abstract: Provided are a hybrid protein comprising a CFH functional unit and a DAF functional unit. an encoding nucleic acid thereof, and a method and use thereof for treating related diseases or disorders of a complement system.

Abstract: This disclosure relates to, inter alia, cells expressing both a chimeric antigen receptor (CAR) and membrane bound IL-12 and the use of these cells to target and treat cancers (e.g., solid tumors and cancers expressing CD19, CD22, BCMA, PSCA, HER2, TAG-72, and PSCA). The disclosure also relates to cells expressing a membrane bound IL-12.